1.

論文(リポジトリ)

論文(リポジトリ)
Nakamura, Hideta ; Ouchi, Gen ; Miyagi, Kazuya ; Higure, Yuuri ; Otsuki, Mariko ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Tateyama, Masao ; Kukita, Ichiro ; Fujita, Jiro
出版情報: The American Journal of Tropical Medicine and Hygene.  104  pp.1018-1021,  2021-01-13.  The American Society of Tropical Medicine and Hygiene
URL: http://hdl.handle.net/20.500.12000/0002019618
概要: Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes. 続きを見る
2.

論文(リポジトリ)

論文(リポジトリ)
Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro
出版情報: Internal Medicine.  59  pp.2945-2949,  2020-11-15.  The Japanese Society of Internal Medicine — 一般社団法人 日本内科学会
URL: http://hdl.handle.net/20.500.12000/47366
概要: Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release synd rome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
論文
続きを見る
3.

論文(リポジトリ)

論文(リポジトリ)
Shiohira, Hideo ; Nakamatsu, Masashi ; Kise, Yuya ; Higa, Futoshi ; Tateyama, Masao ; Hokama, Nobuo ; Kuniyoshi, Yukio ; Ueda, Shinichiro ; Nakamura, Katsunori ; Fujita, Jiro
出版情報: YAKUGAKU ZASSHI.  136  pp.1313-1317,  2016-09-01.  The Pharmaceutical Society of Japan — 日本薬学会
URL: http://hdl.handle.net/20.500.12000/46425
概要: Teicoplanin, a glycopeptide antibiotic for methicillin-resistant Staphylococcus aureus, is recommended for therapeutic d rug monitoring during treatment. Maintaining a high trough range of teicoplanin is also recommended for severe infectious disease. However, the optimal dose and interval of treatment for severe renal impairment is unknown. We report a 79-year-old man who received long-term teicoplanin treatment for methicillin-resistant Staphylococcus aureus bacteremia due to postoperative sternal osteomyelitis with renal impairment. Plasma teicoplanin trough levels were maintained at a high range (20-30 μg/mL). Although the patient required long-term teicoplanin treatment, a further decline in renal function was not observed, and blood culture remained negative after the start of treatment. Teicoplanin treatment that is maintained at a high trough level by therapeutic drug monitoring might be beneficial for severe methicillin-resistant Staphylococcus aureus infection accompanied by renal impairment.
論文
続きを見る